A Phase 3 interventional study of Ranibizumab and Dexamethasone Implant in Visual Impairment, Macular Edema and Branch Retinal Vein Occlusion, sponsored by Novartis Pharmaceuticals. Completed at 66 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-08-07.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies testing ranibizumab in Vision Disorders — none open to participants now, none under way, none of them phase 3. Ranibizumab · Vision Disorders.
Among the 26 studies testing ranibizumab in Vision Disorders, this one is the 9th largest by enrollment, is one of 4 that started in 2011, is one of 14 in phase 3, and was the 10th registered.
361 studies on the registry are indexed under Vision Disorders; 85 are open to participants now.
Browse Vision Disorders studies →None of the 26 studies testing ranibizumab in Vision Disorders is open now. The open studies under Vision Disorders, anywhere →
Ranibizumab: first FDA approval 2006 (LUCENTIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 46 Vision Disorders studies recruiting now, 21 (46%) set no upper age limit and 16 (35%) stop at 75 or younger; 18 take children under 18; 13 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 4 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 244 is above the median of 75 across 245 interventional studies indexed under Vision Disorders.
Median enrollment 178 across the 26 interventional studies. Of the 22 that completed or were terminated, 19 (86%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 26 have an industry lead sponsor. The 6 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
32 studies in Vision Disorders by Novartis: none open now, none under way, none of them phase 3. Of 30 finished, 25 (83%) have results posted.
Among the 32 studies in Vision Disorders by Novartis, this one is the 13th largest by enrollment of the 31 interventional ones that give a count, is one of 5 that started in 2011, is one of 17 in phase 3, and was the 6th registered.
Novartis’s Vision Disorders studies by the year they started, since 2009.
None of the studies under way reaches primary completion within a year.
Among the 26 studies testing ranibizumab in Vision Disorders, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 32 in Vision Disorders:
This tab as a report to print or save as PDF → With an account.
This clinical trial is designed to compare ranibizumab in comparison with Dexamethasone implant after 6 months of treatment. In the study arm Ranibizumab will be given monthly in a pro re nata scheme whereas the comparator Dexamethasone implant is given once at Month 0 with sham injections PRN afterwards.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply
Injections consisted of 0.5 mg/0.05 ml solution to be injected intravitreally
Drug: Ranibizumab
Intravitreal implant as per commercial label (700 μg Dexamethasone; long acting release (LAR) over 6 months
Other: Dexamethasone Implant · Other: Sham injection
Injections consisted of 0.5 mg/0.05 ml solution to be injected intravitreally. Ranibizumab was formulated as a sterile solution aseptically filled in a sterile glass vial. It was suitable for single use only and the content of the vial was not allowed to be split
Comparator Ozurdex® (dexamethasone) was formulated as a rod shaped implant to be inserted into the eye by an applicator. The implant as well as the respective applicator were suitable for single use only.
Sham injection: Empty sterile syringes were provided so that masking could be maintained. Either empty syringes in the case of sham injections or pre-filled syringes in the case of ranibizumab injections were visible to the patient in the room of study drug administration
Mean Average Best Corrected Visual Acuity (BCVA) Change From Month 1 Through Month 6 to Baseline
the average of the changes in BCVA (letters) from baseline to any post-baseline visit, i.e. the mean of six differences to baseline for the six post-baseline visits at month 1 to 6
Time frame: Baseline, month 6
Mean BCVA Change From Baseline to Endpoints Month 1 to Month 6
The analysis was performed by an analysis of covariance (ANCOVA) model with average change in BCVA (letters) from Visit 1 through Visit 6 as dependent variable, and with the factors center, treatment and covariate baseline BCVA as predictors
Time frame: Baseline, month 6
Percentage of Patients Gaining / Losing ≥ 15 / 10 / 5 Letters After 6 Month Treatment
BCVA score was based on the number of letters read correctly on the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart assessed at a starting distance of 4 meters. An ETDRS visual acuity score of 85 is approximately 20/20. An increased score indicates improvement in acuity. This outcome assessed the percentage of participants who gained 15, 10 or 5 more letters of visual acuity at month 6 as compared with baseline
Time frame: Baseline, 6 month
Time to Achieve a Significant Improvement ≥ 15 Letters
The time was analyzed by the Kaplan-Maier-Method, adjusting the calculation for dropouts
Time frame: Baseline, month 6
Change Over Time in BCVA
The analysis was performed by an analysis of covariance (ANCOVA) model with average change in BCVA (letters) from Visit 1 through Visit 6 as dependent variable, and with the factors center, treatment and covariate baseline BCVA as predictors
Time frame: baseline, month 6
Change Over Time of the Central Retinal Thickness (CRT)
Retinal thickness was measured using Optical Coherence Tomography (OCT). The images were reviewed by a central reading center to ensure a standardized evaluation
Time frame: Baseline, month 6
Changes in the Quality of Life According to the National Eye Institute Visual Function Questionnaire (NEI-VFQ 25) Questionnaires
The VFQ-25 composite and subscale scores range from 0 to 100, a higher score indicating better functioning. The 12 subscales in the VFQ-25 are general health, general vision, ocular pain, near activities, distance activities, social function, mental health, role difficulties, dependency, driving, color vision, and peripheral vision. The scores on the subscales were added together for a total score, which ranged from 0 to 100. A higher score indicated improvement in quality of life due to vision function.
Time frame: Baseline, month 6
Changes in the Quality of Life According to the Short Form (36) Health Survey (SF-36)Questionnaires
SF-36 summary measures are norm-based scores with mean = 50 and SD = 10. Higher scores indicate better health
Time frame: Baseline, month 6
Changes in the Quality of Life According to Euro Quality of Life (EQ-5D) Questionnaires
The EQ-5D visual analog scale ranges from 0 to 100, 0 representing the worst and 100 the best imaginable health state.
Time frame: Baseline, month 6
Rate of the Internal Ocular Pressure (IOP)
The proportion of patients with ≥ 10% increase in IOP compared to baseline at any post-baseline visit.
Time frame: Baseline, month 6
| Milestone | Ranibizumab | Dexamethasone |
|---|---|---|
| Started | 126 | 118 |
| Completed | 115 | 100 |
| Not completed | 11 | 18 |
| Withdrew: Adverse event | 2 | 6 |
| Withdrew: Unsatisfactory therapeutic effect | 2 | 6 |
| Withdrew: Protocol deviation | 4 | 4 |
| Withdrew: Consent withdrawn | 3 | 2 |
the average of the changes in BCVA (letters) from baseline to any post-baseline visit, i.e. the mean of six differences to baseline for the six post-baseline visits at month 1 to 6
| Letters | Ranibizumab | Dexamethasone |
|---|---|---|
| Mean Average Best Corrected Visual Acuity (BCVA) Change From Month 1 Through Month 6 to Baseline | 14.9 ± 9.9 | 10.1 ± 9.5 |
The analysis was performed by an analysis of covariance (ANCOVA) model with average change in BCVA (letters) from Visit 1 through Visit 6 as dependent variable, and with the factors center, treatment and covariate baseline BCVA as predictors
| Letters (EDTRS) | Ranibizumab | Dexamethasone |
|---|---|---|
| Mean BCVA Change From Baseline to Endpoints Month 1 to Month 6 | 16.18 (14.04 to 18.32) | 8.10 (5.79 to 10.40) |
BCVA score was based on the number of letters read correctly on the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart assessed at a starting distance of 4 meters. An ETDRS visual acuity score of 85 is approximately 20/20. An increased score indicates improvement in acuity. This outcome assessed the percentage of participants who gained 15, 10 or 5 more letters of visual acuity at month 6 as compared with baseline
| Participants | Ranibizumab | Dexamethasone |
|---|---|---|
| Gain≥15 letters | 77 | 44 |
| Loss of ≥15 letters | 0 | 6 |
| Gain ≥10 letters | 97 | 63 |
| Loss of ≥10 letters | 2 | 8 |
| Gain ≥5 letters | 108 | 76 |
| Loss of ≥5 letters | 4 | 14 |
The time was analyzed by the Kaplan-Maier-Method, adjusting the calculation for dropouts
| Time to event (Days) | Ranibizumab | Dexamethasone |
|---|---|---|
| Time to Achieve a Significant Improvement ≥ 15 Letters | 63 (56 to 84) | 64 (59 to 126) |
The analysis was performed by an analysis of covariance (ANCOVA) model with average change in BCVA (letters) from Visit 1 through Visit 6 as dependent variable, and with the factors center, treatment and covariate baseline BCVA as predictors
| Letters | Ranibizumab | Dexamethasone |
|---|---|---|
| Month 1 | 10.35 (8.53 to 12.17) | 10.44 (8.48 to 12.40) |
| Month 2 | 13.84 (12.04 to 15.64) | 12.62 (10.69 to 14.56) |
| Month 3 | 15.52 (13.44 to 17.59) | 9.16 (6.92 to 11.39) |
| Month 4 | 14.39 (12.38 to 16.41) | 8.59 (6.42 to 10.76) |
| Month 5 | 14.65 (12.52 to 16.78) | 9.08 (6.79 to 11.37) |
| Month 6 | 16.18 (14.04 to 18.32) | 8.10 (5.79 to 10.40) |
Retinal thickness was measured using Optical Coherence Tomography (OCT). The images were reviewed by a central reading center to ensure a standardized evaluation
| µm | Ranibizumab | Dexamethasone |
|---|---|---|
| Change Over Time of the Central Retinal Thickness (CRT) | -230.6 ± 169.3 | -112.3 ± 172.1 |
The VFQ-25 composite and subscale scores range from 0 to 100, a higher score indicating better functioning. The 12 subscales in the VFQ-25 are general health, general vision, ocular pain, near activities, distance activities, social function, mental health, role difficulties, dependency, driving, color vision, and peripheral vision. The scores on the subscales were added together for a total score, which ranged from 0 to 100. A higher score indicated improvement in quality of life due to vision function.
| Score on a scale | Ranibizumab | Dexamethasone |
|---|---|---|
| Changes in the Quality of Life According to the National Eye Institute Visual Function Questionnaire (NEI-VFQ 25) Questionnaires | 7.2 ± 10.2 | 2.8 ± 12.6 |
SF-36 summary measures are norm-based scores with mean = 50 and SD = 10. Higher scores indicate better health
| Units on a scale | Ranibizumab | Dexamethasone |
|---|---|---|
| SF-36 physical component (n=121,114) | -1.1 ± 5.7 | -0.4 ± 5.7 |
| SF-36 mental component (n=121,114) | 3.3 ± 9.2 | 0.2 ± 9.6 |
The EQ-5D visual analog scale ranges from 0 to 100, 0 representing the worst and 100 the best imaginable health state.
| Units on a scale | Ranibizumab | Dexamethasone |
|---|---|---|
| Changes in the Quality of Life According to Euro Quality of Life (EQ-5D) Questionnaires | 0.7 ± 15.2 | -2.4 ± 15.4 |
The proportion of patients with ≥ 10% increase in IOP compared to baseline at any post-baseline visit.
| Participants | Ranibizumab | Dexamethasone |
|---|---|---|
| Rate of the Internal Ocular Pressure (IOP) | 79 | 106 |
Non-serious events are listed at a 2.5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ranibizumab | — | 7/126 (5.6%) | 71/126 (56.3%) |
| Dexamethasone | — | 9/118 (7.6%) | 89/118 (75.4%) |
| Event | Ranibizumab | Dexamethasone |
|---|---|---|
| CONJUNCTIVITIS (Study eye)Eye disorders | 0/126 | 1/118 |
| OCULAR HYPERTENSION (Study eye)Eye disorders | 0/126 | 1/118 |
| ABDOMINAL HERNIAGastrointestinal disorders | 0/126 | 1/118 |
| INGUINAL HERNIAGastrointestinal disorders | 0/126 | 1/118 |
| RECTAL HAEMORRHAGEGastrointestinal disorders | 0/126 | 1/118 |
| UMBILICAL HERNIAGastrointestinal disorders | 0/126 | 1/118 |
| APPENDICITISInfections and infestations | 0/126 | 1/118 |
| BRONCHITISInfections and infestations | 0/126 | 1/118 |
| CELLULITIS (Study eye)Infections and infestations | 0/126 | 1/118 |
| FOOT FRACTUREInjury, poisoning and procedural complications | 0/126 | 1/118 |
| Event | Ranibizumab | Dexamethasone |
|---|---|---|
| OCULAR HYPERAEMIA (Study eye)Eye disorders | 16/126 | 21/118 |
| NASOPHARYNGITISInfections and infestations | 20/126 | 21/118 |
| INTRAOCULAR PRESSURE INCREASEDInvestigations | 3/126 | 19/118 |
| INTRAOCULAR PRESSURE INCREASED (Study eye)Investigations | 2/126 | 17/118 |
| CONJUNCTIVAL HAEMORRHAGE (Study eye)Eye disorders | 12/126 | 14/118 |
| EYE PAIN (Study eye)Eye disorders | 9/126 | 13/118 |
| HEADACHENervous system disorders | 13/126 | 11/118 |
| OCULAR DISCOMFORT (Study eye)Eye disorders | 2/126 | 8/118 |
| FOREIGN BODY SENSATION IN EYES (Study eye)Eye disorders | 8/126 | 4/118 |
| MACULAR OEDEMA (Study eye)Eye disorders | 4/126 | 7/118 |
| Age, Continuous(Years) | Ranibizumab | Dexamethasone | Total |
|---|---|---|---|
| Mean | 65.7 ± 10.9 | 65.6 ± 10.0 | 65.6 ± 10.5 |
| Sex: Female, Male(Participants) | Ranibizumab | Dexamethasone | Total |
|---|---|---|---|
| Female | 76 | 57 | 133 |
| Male | 50 | 61 | 111 |
The record gives a start of Jul 2011, a primary completion of Jun 2013 and a completion of Jun 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2014, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ranibizumab